News
-
Xcovery Announces Presentation Of Clinical Data At Upcoming ASCO Annual Meeting
5/18/2012
Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced that investigators will present data from its Phase 1 clinical study which evaluated X-82, an oral VEGFR tyrosine kinase inhibitor (TKI), in patients with advanced solid tumors.
-
BASi Adds Director Of Discovery Services, Expands West Lafayette Research Collaborative Opportunities
5/15/2012
BASi (Bioanalytical Systems Inc.) has named David Reynolds as its director of discovery services. Reynolds will oversee studies and staff of the company’s new Discovery Center at corporate headquarters in West Lafayette, Ind.
-
Abbott Presents Positive Results From Phase 2 "Pilot" Study Of An Interferon-Free Combination Regimen For The Treatment Of Hepatitis C
4/19/2012
Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced complete data from the study known as "Pilot" – Abbott's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepatitis C (HCV) – showing that 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
-
AMRI Signs Exclusive Option To License Its Tubulin Inhibitor Program For Cancer
4/9/2012
AMRI, a global contract healthcare services organization spanning the entire R&D continuum, announced recently that it has signed an exclusive option to enter a license agreement with Bessor Pharma, LLC a translational drug development company led by industry veteran Barry A. Berkowitz, Ph.D., for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer.
-
Shire To Acquire FerroKin BioSciences, Inc., And Its Phase 2 Iron Chelator Treatment
3/19/2012
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
-
Celerion And Ricerca Biosciences Announce ‘The Biosimilars Alliance’ To Offer Clients A More Effective Development Path For Biosimilars
3/1/2012
Celerion, the premier provider of innovative early stage drug development solutions, and Ricerca Biosciences, a drug safety assessment expert in harnessing external preclinical innovation, announce the formation of “The Biosimilars Alliance”.
-
BARDA Awards Contract Worth Up To $67M For The Development Of A Novel Tetraphase Antibiotic
2/21/2012
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, recently announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67M for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product candidate in Tetraphase's clinical pipeline.
-
Absorption Systems Expands In Vivo Drug Testing Capabilities
2/1/2012
Absorption Systems announces the latest in a series of milestones in the continuing expansion of its AAALAC-accredited and GLP-compliant facility in San Diego, CA.
-
Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors
1/10/2012
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
-
Absorption Systems Initiates Collaboration With Academic Researchers To Develop Improved In Vitro Pharmacokinetic Predictions
10/3/2011
In a collaborative effort, Absorption Systems is working with Drs. Ken Korzekwa and Swati Nagar of Temple University and Dr. Jeff Jones of Washington State University to develop technologies to improve the predictive power of certain in vitro-in vivo correlations (IVIVCs).